BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  GLP-1

  BioSpace Presents the World Atlas of GLP-1s

  Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the territory covered and what’s to come.

  March 26, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  FDA

  GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years

  Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in the second half of this year.

  March 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Biosimilars

  Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise

  AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market.

  March 26, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Podcast

  Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More

  President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.

  March 26, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Alzheimer’s disease

  Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake

  Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.

  March 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Senate Confirms Makary as FDA Chief as Trump’s Health Nominees Move Forward

  Marty Makary earlier this month distanced himself from the recent shake-ups at the FDA, including the cancellation of its vaccines advisory committee meeting and the steep layoffs at the agency.

  March 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Duchenne muscular dystrophy

  Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial

  WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.

  March 26, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  China

  Bayer Jumps on Chinese Partnership Train with Oncology Deal

  The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.

  March 26, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Manufacturing

  GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

  With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

  March 26, 2025

   · 

  6 min read

   · 

  Ben Hargreaves
• 

  Government

  Tariffs Would Impede Access to Affordable Drugs, Industry Warns

  Donald Trump’s proposed tariffs on the EU would increase manufacturing costs for pharma companies and would stall medical innovation, according to the results of a recent survey by the Biotechnology Innovation Organization.

  March 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac